Updated:
Facet Life Sciences
Ken VanLuvanee leads Facet Life Sciences, a regulatory-affairs firm guiding small biotech companies from discovery to FDA approval.
Facet Life Sciences
Facet Life Sciences was founded to help emerging life science companies navigate Food and Drug Administration regulatory pathways. Ken VanLuvanee serves as CEO and Board Chairman; the firm's management team includes several Ph.D. and RAC-certified professionals. The firm provides full-lifecycle regulatory support: regulatory strategy, medical writing, statistical services, and asset valuation. It works across drug, biologic, and medical device categories, and across dosage forms. Facet cites experience with Phase 3 programs and NDA submissions; client testimonials mention a novel chemical entity IND filing in 18 months and an NDA approval six weeks after database lock. The firm operates in North America, with offices in Wayne, Pennsylvania; Portland, Lake Oswego, and Bend, Oregon; and San Mateo, California. Facet publishes no AUM or deployment data. Its team includes dozens of named professionals, many with advanced degrees and regulatory certification. The firm lists no separate philanthropic or investment vehicles. Facet's structural differentiator is its focus exclusively on small and mid-size life science companies, positioning itself as a regulatory partner rather than a contract research organization or large consultant. Its mandate is to translate scientific innovation into FDA-ready submissions, not to manage third-party capital.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Wayne
Corporate office
Wayne, PA, United States
Additional offices
Portland, OR · Lake Oswego, OR · San Mateo, CA · Bend, OR
Principals
Ken VanLuvanee
CEO and Board Chairman
Lisa Jenkins VanLuvanee, Ph.D.
Chief Values Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Facet Life Sciences?
Ken VanLuvanee serves as CEO and Board Chairman. The firm has not disclosed any separate investment committee or CIO role; its activities appear to focus on regulatory consulting rather than asset management.
Is Facet Life Sciences a family office or a consulting firm?
Facet Life Sciences describes itself as a regulatory strategy and product development partner for small biotech companies. It does not present itself as managing third-party capital or as a family office; its revenue model is fee-for-service, not investment returns.
How does Facet Life Sciences source proprietary deal flow?
Facet does not publicly describe a proprietary sourcing model. Client testimonials on its website suggest that engagement typically begins when a small biotech company requires regulatory guidance for a specific product development program.
Does Facet Life Sciences participate in fund commitments or only direct deals?
Facet Life Sciences reports no fund commitments. Its operations are limited to providing regulatory, medical writing, statistical, and asset valuation services to life science companies.
What investment stages does Facet Life Sciences typically target?
Facet's website outlines support across the full product development lifecycle, from discovery and preclinical research through clinical trials, IND/IDE submissions, marketing applications, and commercial launch. It does not specify a preferred stage for engagement.
Which sectors does Facet Life Sciences explicitly avoid?
Facet does not publish a list of avoided sectors. Its stated therapeutic experience spans all therapeutic areas and most dosage forms, suggesting broad sector coverage within life sciences.
Does Facet Life Sciences maintain philanthropic structures, and how are they separated?
Facet Life Sciences does not disclose any separate philanthropic foundation or charitable vehicle. No such entity is mentioned on its website or in available public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: